14%: The Number Behind South Africa’s GLP-1 Spending Shift
Some numbers describe behaviour. Others expose a mood.
14% belongs in the second category.
That is the share of surveyed credit card holders earning above R100,000 a year who say they are spending on prescribed weight-management medication, including GLP-1 therapies. On its own, that sounds like a clean consumer trend. In reality, it points to something more layered: a mix of aspiration, anxiety, affordability, and a growing willingness to spend heavily on body-related outcomes.
The number becomes even more revealing when placed beside the rest of the same survey. Another 16% report spending on dieticians or weight-loss clinics. That suggests a broader reordering of health and wellness budgets, not just a flash of hype around one category of medication. Weight management is not sitting at the edges of discretionary spending anymore. For a meaningful slice of wealthier consumers, it is moving closer to the centre.
But the tension around these medicines does not begin and end with demand.
It begins with what people think they are buying.
The attraction is obvious. GLP-1 medicines have built a global reputation around fast, visible results. They are discussed like breakthrough tools, spoken about with the urgency usually reserved for tech launches or financial hacks. That kind of cultural momentum matters. It changes how people see health. It changes how people spend. It changes how quickly a product moves from specialist treatment into mainstream ambition.
Yet the caution is not some distant footnote. It sits right in the middle of the story.
The discussion between Gareth Edwards and Francis Herd leans into that discomfort. The question is not only whether the drugs can help people lose weight. The harder question is what happens after that. What happens when treatment stops? What happens when people who are not using the medicines for their original clinical purpose start treating them like a shortcut with no long tail? The transcript keeps circling that concern, pushing past trend language and back into consequences.
That unease becomes sharper in South Africa because access is already uneven. These medicines are not available in the public sector, and in the private market they remain expensive. Spotlight reports that weight-management doses of semaglutide and tirzepatide generally cost between about R3,000 and R6,000 a month, sometimes more. That means the category is growing, but mostly among people with enough income, enough cover, or enough urgency to absorb the cost.
That matters because it changes what the 14% really tells us.
It is not a national measure of uptake. It is a signal from a specific slice of the market. A slice with money.
A slice with access. A slice already reshaping spending in ways that may preview a wider future if prices fall and availability grows.
And that wider future may not be far off. Wegovy launched in South Africa in 2025 specifically for weight management. Mounjaro followed a similar trajectory, first as a diabetes treatment and then with local approval for weight management too. Sales have accelerated sharply, even while affordability remains a barrier.
So the real story inside 14% is not simply that people are buying weight-loss drugs.
It is that South Africans with means are already reorganising their budgets around them. It is that health spending is starting to look more like identity spending. It is that demand is rising faster than public certainty. And it is that a market can move quickly even while the social, ethical, and medical questions remain messy.
That is why 14% lands.
Not because it is huge. Because it feels early.
And early numbers like that tend to matter most when they hint at where the culture, the market, and the pressure are heading next.
This pack applies the locked house rules you flagged: no generic “in this episode” framing, no “this clip” phrasing, and no publication names inside the body copy itself.
Catch up on all Number of the Day episodes here: https://www.enca.com/number-day-podcast